[Asia Economy Reporter Jang Hyowon] BioInfra completed its public offering subscription for general investors over two days from the 20th to the 21st, recording a competition rate of 1,034.7 to 1. The subscription deposit amounted to approximately 1.7655 trillion KRW.
Earlier, BioInfra (CEO Lee Sangdeuk), a clinical trial specimen analysis specialist company, recorded a competition rate of 1,594.9 to 1 during the demand forecast for domestic and international institutional investors over two days from the 13th to the 14th, and finalized the public offering price at the top end of the offering band, 21,000 KRW, within the range of 18,000 to 21,000 KRW.
BioInfra is a contract research organization (CRO) specializing in conducting research and development on behalf of developers during the pharmaceutical R&D phase. The company’s main revenue sources include bioequivalence testing, Phase 1 clinical trials, and clinical/non-clinical specimen analysis.
After listing, the company is expected to continue its growth through expanded new investments. In particular, it plans to develop an automated specimen analysis and data processing system to completely eliminate human error and dramatically improve specimen analysis quality.
CEO Lee Sangdeuk of BioInfra stated, “Taking this KOSDAQ listing as an opportunity, we will expand our business areas and pursue entry into the ASEAN market to grow into a global CRO company centered on analytical technology.”
Meanwhile, BioInfra is scheduled to enter the KOSDAQ market on March 2. The lead underwriter is DB Financial Investment.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
